4 completed, 2 recruiting, 1 not yet recruiting, 1 no longer available. 3 Phase 1, 2 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Cholangiocarcinoma, Extrahepatic: new trials by email Literature Review of Cholangiocarcinoma, Extrahepatic trials Research Report on Cholangiocarcinoma, Extrahepatic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer BTC-Ag-T (ACH-AgT001), Cyclophosphamide and Fludarabine - Biliary Tract Neoplasms, Cholangiocarcinoma, Intrahepatic | Phase 1 | Recruiting | Shanghai Zhongshan Hospital | 18 | 2026-05-01 | 2026-05-29 |
| TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA) | Not yet recruiting | Aarhus University Hospital | 300 | 2026-03-15 | 2026-03-06 | |
| Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot Study Endoscopic retrograde cholangiopancreatography (ERCP) - Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma of the Extrahepatic Bile Duct | Not applicable | Recruiting | University Hospital Olomouc | 20 | 2023-02-04 | 2025-07-02 |
| Recurrence After Whipple's (RAW) Study Pancreaticoduodenectomy - Pancreatic Cancer, Ampullary Cancer | Completed | University Hospital Plymouth NHS Trust | 1484 | 2020-10-12 | 2023-11-18 | |
| Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors Robotic pancreaticoduodenectomy, Open pancreaticoduodenectomy - Pancreatic Adenocarcinoma, Pancreatic Cysts | Not applicable | Completed | Ruijin Hospital | 268 | 2020-09-28 | 2025-12-18 |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors LMB-100, Tofacitinib, Mesothelin Expression - Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma | Phase 1 | Completed | National Cancer Institute (NCI) | 19 | 2019-08-29 | 2023-08-01 |
| A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma ABC294640, Hydroxychloroquine Sulfate 200 MG - Cholangiocarcinoma, Cholangiocarcinoma Non-resectable | Phase 2 | Completed | RedHill Biopharma Limited | 65 | 2018-03-07 | 2025-07-23 |
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma PEGPH20, CIS, GEM - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic | Phase 1 | Terminated | Halozyme Therapeutics | 85 | 2017-10-02 | 2020-02-07 |
| Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®) ABC294640 - Cholangiocarcinoma, Cholangiocarcinoma Non-resectable | No longer available | RedHill Biopharma Limited | 2025-03-18 |
Cholangiocarcinoma (9) · Klatskin Tumor (5) · Biliary Tract Neoplasms (2) · Gallbladder Neoplasms (2) · Pancreatic Neoplasms (2) · Recurrence (2) · Adenocarcinoma (1) · Bile Duct Neoplasms (1) · Carcinoma, Pancreatic Ductal (1) · Disease (1) · Neoplasm, Residual (1) · Neoplasms (1) · Pancreatic Cyst (1) · Pancreatitis, Chronic (1)
Carcinoma (9) · Neoplasms by Histologic Type (9) · Neoplasms, Glandular and Epithelial (9) · Adenocarcinoma (8) · Neoplasms (8) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Neoplasms by Site (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Biliary Tract Diseases (3) · Disease Attributes (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Gallbladder Diseases (2)
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (2) · Cholangiopancreatography, Endoscopic Retrograde (1) · Cyclophosphamide (1) · Hydroxychloroquine (1) · LMB-100 (1) · PEGPH20 (1) · Pancreaticoduodenectomy (1) · atezolizumab (1) · fludarabine (1) · tofacitinib (1)
RedHill Biopharma Limited (2) · Aarhus University Hospital (1) · Halozyme Therapeutics (1) · National Cancer Institute (NCI) (1) · Ruijin Hospital (1) · Shanghai Zhongshan Hospital (1) · University Hospital Olomouc (1) · University Hospital Plymouth NHS Trust (1)
United States (3) · China (2) · Australia (1) · Austria (1) · Czechia (1) · Denmark (1) · Italy (1) · Mexico (1) · Pakistan (1) · South Korea (1) · Spain (1) · Sudan (1) · Thailand (1) · United Kingdom (1)
Baiyong Shen, PhD (1) · Christine C Alewine, M.D. (1) · Guoming Shi, MD, PhD (1) · Karen-Lise Garm Spindler, Professor, MD, PhD (1) · Lise Thorsen, Associate professor, MD, PhD (1) · Mitesh Borad, MD (1) · Mohamed Metwally, Consultant, MD, PhD (1) · Somaiah Aroori (1)
PMID 28420720, PMID 34961558, PMID 38701690, PMID 38706610, PMID 42386316